Lutetium Lu 177 Zadavotide Guraxetan clinical trials
Also written [177Lu]Lu-PSMA I&T and 177Lu-PNT2002.
How each study uses Lutetium Lu 177 Zadavotide Guraxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Lutetium Lu 177 Zadavotide Guraxetan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 8
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2) · Medical University of Vienna (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Jonsson Comprehensive Cancer Center (1) · POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company (1) · Glenn Bauman (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Lutetium Lu 177 Zadavotide Guraxetan.
- Jan 2027Neoadjuvant PSMA-RLT in Oligometastatic PCaPhase 2 · Medical University of Vienna
- Sep 2027Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)Phase 2 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Studies
Open first, then newest update. How each study uses Lutetium Lu 177 Zadavotide Guraxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)RecruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT05893381Written as [177Lu]Lu-PSMA I&THow we know
- Neoadjuvant PSMA-RLT in Oligometastatic PCaRecruitingPhase 2Medical University of ViennaNCT06259123Written as [177Lu]Lu-PSMA I&THow we know
- PSMA-RLT in Biochemically Recurrent PCaRecruitingPhase 2Medical University of ViennaNCT06220188Written as [177Lu]Lu-PSMA I&THow we know
- 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR StudyActive, not recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT05496959Written as Lutetium Lu-177 PNT2002How we know
- 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic CarcinomaTerminatedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06322576Written as 177Lu-PNT2002How we know
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentActive, not recruitingPhase 3POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyNCT04647526Written as [Lu-177]-PNT2002How we know
- Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:Active, not recruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT05867615Written as [177Lu]Lu-PSMA I&THow we know
- Radioligand fOr locAl raDiorecurrent proStaTe cancERCompletedPhase 1/2Glenn BaumanNCT05230251Written as 177Lu-PNT2002How we know
- PSMA Therapy and Immunotherapy in Kidney CancerWithdrawnPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06361810Written as 177Lu-PNT2002How we know
Codes
What other systems call Lutetium Lu 177 Zadavotide Guraxetan · ClinicalTrials.gg INT016632
- UNII (FDA) G5B860B0G1LUTETIUM LU-177 ZADAVOTIDE GURAXETANOne source FDA
- NCI Thesaurus C184831Lutetium Lu 177 Zadavotide GuraxetanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | G5B860B0G1 | LUTETIUM LU-177 ZADAVOTIDE GURAXETAN | One source FDA |
| NCI Thesaurus | C184831 | Lutetium Lu 177 Zadavotide Guraxetan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.